FDA DEVICE FACTS
MI Cancer Seek
Caris Life Sciences
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
MI Cancer Seek is a next-generation sequencing (NGS) based in vitro diagnostic (IVD) device using total nucleic acid (TNA) isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens for the detection of single nucleotide variants (SNVs) and insertions and deletions (indels) in 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB) in patients with previously diagnosed solid tumors, and copy number amplification (CNA) in one gene in patients with breast cancer. MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 below, in accordance with the approved therapeutic product labeling. Additionally, MI Cancer Seek is intended to provide tumor mutational profiling to be used by qualified healthcare professionals in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.
Table 1. MI Cancer Seek Companion Diagnostic Indications Indication Biomarker Therapy Breast Cancer PIK3CA (C420R; E542K; E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and H1047L, H1047R, H1047Y) PIQRAY® (alpelisib) Colorectal Cancer (CRC) KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4) VECTIBIX® (panitumumab) BRAF V600E BRAFTOVI® (encorafenib) in combination with ERBITUX® (cetuximab) Melanoma BRAF V600E BRAF Inhibitors approved by FDA* BRAF V600E or V600K MEKINIST® (trametinib) or BRAF/MEK Inhibitor Combinations approved b y FDA* Non-small cell lung cancer (NSCLC) EGFR exon 19 deletions and exon 21 L858R alterations EGFR Tyrosine Kinase Inhibitors approved by FDA* Solid Tumors MSI-H KEYTRUDA® (pembrolizumab), JEMPERLI (dostarlimab-gxly) Endometrial Carcinoma Not MSI-H KEYTRUDA® (pembrolizumab) in combination with LENVIMA® (lenvatinib) *For the most current information about the device indications for the therapeutic products in this group, go to: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools#Group_Labeling MI Cancer Seek is a single-site assay performed at Caris Life Sciences, Phoenix, AZ.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。